The mystery of COVID-19: More questions emerge

Abstract

New coronavirus, with the other name of SARS-Cov-2, first emerged in China's Wuhan city of Hubei province in December 2019. The virus causes a disease varying from asymptomatic course to acute respiratory distress syndrome or multiple organ failure. The disease caused by this virus discovered in 2019 named Coronavirus Disease-19 (COVID-19), and then, a global epidemic (pandemic) has been declared on March 11, 2020, byWorld Health Organization (WHO).1,2 Since COVID-19 cases have similar symptoms, clinical and laboratory findings with SARS-Cov and MERS-Cov patients, previously performed studies thought to be a pathfinder to define the pathogenesis of the disease.2,3 However, there are still some unsolved issues for the various aspects of COVID-19, although more than six months passed from the appearance of the first case in China. Of course, scientists have been studying the coronavirus to spread reliable life-saving information, as well as combating dangerous misunderstandings. Here are some of the most important questions to solve the mystery of COVID-19.

Keywords

• COVID
• Immun system
• mystery

References

1. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15;395(10223):514-23. doi: 10.1016/S0140-6736(20)30154-9.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.
3. Peiris JS, Yuen KY, Osterhaus AD, Stöhr K. The severe acute respiratory syndrome. N Engl J Med. 2003 Dec 18;349(25):2431-41. doi: 10.1056/NEJMra032498.
4. Li X, Giorgi EE, Marichannegowda MH, Foley B, Xiao C, Kong XP, Chen Y, Korber B, Gao F. Emergence of SARS-CoV-2 through recombination and strong purifying selection. Sci Adv. 2020 July 1;6(27):eabb9153. doi: 10.1126/sciadv.abb9153.
5. Available from: https://www.nbcnews.com/health/health-news/cdc-says-covid-19-cases-u-s-may-be-10-n1232134. (cited Jul 2020).
6. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, Borgert BA, Moreno CA, Solomon BD, Rodriguez-Barraquer I, Lessler J, Salje H, Burke D, Wesolowski A, Cummings DAT. A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease. medRxiv. 2020 Apr 17:2020.04.14.20065771. doi: 10.1101/2020.04.14.20065771. Available from: https://www.medrxiv.org/content/10.1101/2020.04.14.20065771v1.
7. Li K, Chen D, Chen S, Feng Y, Chang C, Wang Z, Wang N, Zhen G. Radiographic findings and other predictors in adults with Covid-19. medRxiv 2020. doi: https://doi.org/10.1101/2020.03.23.20041673. Available from: https://www.medrxiv.org/content/10.1101/2020.03.23.20041673v1.
8. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, Lamers MM, Sikkema RS, de Bruin E, Chandler FD, Yazdanpanah Y, Le Hingrat Q, Descamps D, Houhou-Fidouh N, Reusken CBEM, Bosch BJ, Drosten C, Koopmans MPG, Haagmans BL. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg Infect Dis. 2020 Jul;26(7):1478-88. doi: 10.3201/eid2607.200841.

9. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S, Hong C, Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L, Zhang J, Xia N, Zhang Z. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020 Mar 28:ciaa344. doi: 10.1093/cid/ciaa344.
10. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-62. doi: 10.1016/S0140-6736(20)30566-3.
11. van der Heide V. Neutralizing antibody response in mild COVID-19. Nat Rev Immunol. 2020 Jun;20(6):352. doi: 10.1038/s41577-020-0325-2.
12. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, Levantovsky R, Malle L, Moreira A, Park MD, Pia L, Risson E, Saffern M, Salomé B, Esai Selvan M, Spindler MP, Tan J, van der Heide V, Gregory JK, Alexandropoulos K, Bhardwaj N, Brown BD, Greenbaum B, Gümüş ZH, Homann D, Horowitz A, Kamphorst AO, Curotto de Lafaille MA, Mehandru S, Merad M, Samstein RM; Sinai Immunology Review Project. Immunology of COVID-19: Current State of the Science. Immunity. 2020 Jun 16;52(6):910-41. doi: 10.1016/j.immuni.2020.05.002.
13. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. (cited Jul 2020).
14. van Doremalen N, Haddock E, Feldmann F, Meade-White K, Bushmaker T, Fischer RJ, Okumura A, Hanley PW, Saturday G, Edwards NJ, Clark MHA, Lambe T, Gilbert SC, Munster VJ. A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques. Sci Adv. 2020 Jun 10;6(24):eaba8399. doi: 10.1126/sciadv.aba8399.
15. Mulligan MJ. Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart SP, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fonter-Garfias C, Shi PY, Tuereci O, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC, Sahin U, Jansen KU. Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report medRxiv 2020.06.30.20142570. doi: 10.1101/2020.06.30.20142570.